Physician profile
Roger N Danziger
NPI 1255395133
$9,587.48
in general payments reported to CMS, 2019-2025
28 companies · $1,737 in 2025
The $1,737 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,235 · 2020: $810 · 2021: $816 · 2022: $1,752 · 2023: $1,705 · 2024: $1,534 · 2025: $1,737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,796 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,795.50 |
| Education | $179.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,485.91 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $1,331.92 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,098.16 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $1,084.91 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Glaxosmithkline, LLC. | $908.30 | 2019-2025 | Nucala, Trelegy Ellipta |
| Csl Behring | $811.01 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Genentech USA, INC. | $582.29 | 2019-2024 | Xolair |
| Adma Biomanufacturing LLC | $298.10 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $253.46 | 2019-2025 | |
| Amgen INC. | $244.32 | 2022-2025 | Tezspire |
| Pharming Healthcare, INC. | $197.60 | 2019-2024 | Ruconest |
| Shire North American Group INC | $185.97 | 2019 | |
| Biocryst US Sales Co., LLC | $159.89 | 2021-2025 | Orladeyo |
| Blueprint Medicines Corporation | $148.53 | 2023-2025 | Ayvakit |
| Apellis Pharmaceuticals, INC. | $121.85 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $119.73 | 2019-2022 | |
| Optinose US, INC. | $105.27 | 2019-2025 | |
| Alk-Abello, INC | $98.68 | 2019-2025 | Timothy, Standardized, Alternaria Tenuis, Standardized Mite D. Farinae |
| Grifols USA, LLC | $71.87 | 2023-2025 | Xembify, Prolastin-C Liquid |
| Ionis Pharmaceuticals, INC. | $59.42 | 2025 | Dawnzera |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.46 | 2019-2021 | |
| Pfizer INC. | $41.48 | 2021-2024 | |
| Octapharma USA, INC. | $31.77 | 2019-2020 | |
| Insmed, INC. | $28.57 | 2025 | Arikayce |
| Lilly USA, LLC | $23.10 | 2025 | Ebglyss |
| Ars Pharmaceuticals Operations, INC. | $22.19 | 2025 | Neffy |
| Azurity Pharmaceuticals, INC. | $16.76 | 2025 | Alvesco |
| Merck Sharp & Dohme LLC | $12.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Danziger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.